Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
1
LENZ Quote, Financials, Valuation and Earnings
Last price:
$23.20
Seasonality move
:
-6.62%
Day range:
$23.10 - $25.82
52-week range:
$14.42 - $38.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.97x
Volume:
212.3K
Avg. volume:
150.2K
1-year change:
15.53%
Market cap:
$638.3M
Revenue:
--
EPS (TTM):
-$5.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | -$0.40 | -- | -57.13% | $39.29 |
|
LFMD
LifeMD
|
$57.4M | $0.14 | 27.32% | -93.33% | $12.00 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.31 | -- | -29.53% | $43.17 |
|
PETS
PetMed Express
|
$60M | -- | -8.14% | -- | -- |
|
STRM
Streamline Health Solutions
|
$5.3M | -- | -24.87% | -- | $22.50 |
|
TBRG
TruBridge
|
$84.4M | $0.38 | -1.77% | -28.23% | $19.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
$23.21 | $39.29 | $638.3M | -- | $0.00 | 0% | -- |
|
LFMD
LifeMD
|
$4.74 | $12.00 | $205.3M | -- | $0.00 | 0% | 0.98x |
|
ORKA
Oruka Therapeutics
|
$15.72 | $43.17 | $550.2M | -- | $0.00 | 0% | -- |
|
PETS
PetMed Express
|
$4.77 | -- | $98.6M | -- | $0.30 | 0% | 0.38x |
|
STRM
Streamline Health Solutions
|
$3.59 | $22.50 | $15.3M | -- | $0.00 | 0% | 0.76x |
|
TBRG
TruBridge
|
$21.40 | $19.20 | $319.4M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | 3.796 | -- | -- |
|
LFMD
LifeMD
|
173.46% | 3.532 | 8.61% | 0.74x |
|
ORKA
Oruka Therapeutics
|
-- | 0.000 | -- | -- |
|
PETS
PetMed Express
|
-- | 0.536 | -- | 1.10x |
|
STRM
Streamline Health Solutions
|
46.84% | 3.886 | 128.9% | 0.41x |
|
TBRG
TruBridge
|
50.52% | 2.010 | 98.74% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | -$12.9M | -- | -- | -- | -$10.8M |
|
LFMD
LifeMD
|
$48.4M | -$4.7M | -141.04% | -- | -8.78% | $2.7M |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
PETS
PetMed Express
|
$17.3M | $554K | -0.96% | -0.96% | 0.93% | $6.1M |
|
STRM
Streamline Health Solutions
|
$2M | -$2M | -32.78% | -54.79% | -44.81% | -$2M |
|
TBRG
TruBridge
|
$41.5M | $1.9M | -16.31% | -31.4% | 1.87% | $4.8M |
LENZ Therapeutics vs. Competitors
-
Which has Higher Returns LENZ or LFMD?
LifeMD has a net margin of -- compared to LENZ Therapeutics's net margin of -9.61%. LENZ Therapeutics's return on equity of -- beat LifeMD's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.38 -- LFMDLifeMD90.61% -$0.14 $12.3M -
What do Analysts Say About LENZ or LFMD?
LENZ Therapeutics has a consensus price target of $39.29, signalling upside risk potential of 69.26%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 147.3%. Given that LifeMD has higher upside potential than LENZ Therapeutics, analysts believe LifeMD is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics4 0 0 LFMDLifeMD7 1 0 -
Is LENZ or LFMD More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LifeMD has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.061%.
-
Which is a Better Dividend Stock LENZ or LFMD?
LENZ Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. LifeMD pays out -15.08% of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or LFMD?
LENZ Therapeutics quarterly revenues are --, which are smaller than LifeMD quarterly revenues of $53.4M. LENZ Therapeutics's net income of -$10.2M is lower than LifeMD's net income of -$5.1M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 0.98x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$10.2M LFMDLifeMD0.98x -- $53.4M -$5.1M
-
Which has Higher Returns LENZ or ORKA?
Oruka Therapeutics has a net margin of -- compared to LENZ Therapeutics's net margin of --. LENZ Therapeutics's return on equity of -- beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.38 -- ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About LENZ or ORKA?
LENZ Therapeutics has a consensus price target of $39.29, signalling upside risk potential of 69.26%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 174.6%. Given that Oruka Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Oruka Therapeutics is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics4 0 0 ORKAOruka Therapeutics6 0 0 -
Is LENZ or ORKA More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or ORKA?
LENZ Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or ORKA?
LENZ Therapeutics quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. LENZ Therapeutics's net income of -$10.2M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$10.2M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns LENZ or PETS?
PetMed Express has a net margin of -- compared to LENZ Therapeutics's net margin of 3.91%. LENZ Therapeutics's return on equity of -- beat PetMed Express's return on equity of -0.96%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.38 -- PETSPetMed Express29.06% $0.11 $96.4M -
What do Analysts Say About LENZ or PETS?
LENZ Therapeutics has a consensus price target of $39.29, signalling upside risk potential of 69.26%. On the other hand PetMed Express has an analysts' consensus of -- which suggests that it could fall by -21.38%. Given that LENZ Therapeutics has higher upside potential than PetMed Express, analysts believe LENZ Therapeutics is more attractive than PetMed Express.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics4 0 0 PETSPetMed Express0 0 0 -
Is LENZ or PETS More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PetMed Express has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.122%.
-
Which is a Better Dividend Stock LENZ or PETS?
LENZ Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetMed Express offers a yield of 0% to investors and pays a quarterly dividend of $0.30 per share. LENZ Therapeutics pays -- of its earnings as a dividend. PetMed Express pays out -166.63% of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or PETS?
LENZ Therapeutics quarterly revenues are --, which are smaller than PetMed Express quarterly revenues of $59.6M. LENZ Therapeutics's net income of -$10.2M is lower than PetMed Express's net income of $2.3M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while PetMed Express's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 0.38x for PetMed Express. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$10.2M PETSPetMed Express0.38x -- $59.6M $2.3M
-
Which has Higher Returns LENZ or STRM?
Streamline Health Solutions has a net margin of -- compared to LENZ Therapeutics's net margin of -56.03%. LENZ Therapeutics's return on equity of -- beat Streamline Health Solutions's return on equity of -54.79%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.38 -- STRMStreamline Health Solutions46.03% -$0.61 $26.2M -
What do Analysts Say About LENZ or STRM?
LENZ Therapeutics has a consensus price target of $39.29, signalling upside risk potential of 69.26%. On the other hand Streamline Health Solutions has an analysts' consensus of $22.50 which suggests that it could fall by -58.22%. Given that LENZ Therapeutics has higher upside potential than Streamline Health Solutions, analysts believe LENZ Therapeutics is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics4 0 0 STRMStreamline Health Solutions1 0 0 -
Is LENZ or STRM More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.552, suggesting its more volatile than the S&P 500 by 55.205%.
-
Which is a Better Dividend Stock LENZ or STRM?
LENZ Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or STRM?
LENZ Therapeutics quarterly revenues are --, which are smaller than Streamline Health Solutions quarterly revenues of $4.4M. LENZ Therapeutics's net income of -$10.2M is lower than Streamline Health Solutions's net income of -$2.5M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 0.76x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$10.2M STRMStreamline Health Solutions0.76x -- $4.4M -$2.5M
-
Which has Higher Returns LENZ or TBRG?
TruBridge has a net margin of -- compared to LENZ Therapeutics's net margin of -11.7%. LENZ Therapeutics's return on equity of -- beat TruBridge's return on equity of -31.4%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.38 -- TBRGTruBridge49.46% -$0.66 $348.9M -
What do Analysts Say About LENZ or TBRG?
LENZ Therapeutics has a consensus price target of $39.29, signalling upside risk potential of 69.26%. On the other hand TruBridge has an analysts' consensus of $19.20 which suggests that it could fall by -10.28%. Given that LENZ Therapeutics has higher upside potential than TruBridge, analysts believe LENZ Therapeutics is more attractive than TruBridge.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics4 0 0 TBRGTruBridge2 2 0 -
Is LENZ or TBRG More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TruBridge has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.412%.
-
Which is a Better Dividend Stock LENZ or TBRG?
LENZ Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or TBRG?
LENZ Therapeutics quarterly revenues are --, which are smaller than TruBridge quarterly revenues of $83.8M. LENZ Therapeutics's net income of -$10.2M is lower than TruBridge's net income of -$9.8M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 0.90x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$10.2M TBRGTruBridge0.90x -- $83.8M -$9.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
